Alzari
Pedro Alzari, Paris FR
Patent application number | Description | Published |
---|---|---|
20100145008 | OB-FOLD USED AS SCAFFOLD FOR ENGINEERING NEW SPECIFIC BINDERS - The present invention pertains to the field of protein engineering, and provides means for obtaining stable molecules that specifically bind to a target selected amongst a large variety of ligands families. In particular, the present invention provides methods for obtaining a molecule specifically binding to a target of interest, through a combinatorial mutation/selection approach with an OB-fold protein as a starting molecule. In particular, the target of interest can be of a different chemical nature form that of the native target of the OB-fold protein used as the starting molecule. | 06-10-2010 |
20100273723 | PEPTIDES OF IL-2 - The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents. | 10-28-2010 |
20130143201 | Crystallographic structure of TcPRACA and uses therefor - A method of identifying a substance that affects the biological activity of a | 06-06-2013 |
Pedro Alzari, Paris Cedex 15 FR
Patent application number | Description | Published |
---|---|---|
20100183645 | ACTIVE OR PASSIVE IMMUNIZATION AGAINST PROAPOPTOTIC NEUROTROPHINS FOR THE TREATMENT AND/OR PREVENTION OF NEURODEGENERATIVE DISEASES - The present invention relates to novel methods for combating cell degeneration or dysfunction resulting from neuroinflammatory conditions. The invention especially relates to the use, in the preparation of a medicament for the treatment of neurodegenerative disease associated with neuroinflammation, of an immunogenic compound which is capable of inducing an immune response against a proapoptotic neurotrophin, or an effective amount of a hapten combined with appropriate carriers and/or adjuvants to render the resulting combination capable of inducing an immune response against a proapoptotic neurotrophin. Also disclosed are compositions for the active or passive immunization against neuronal or glial cell apoptosis caused by neuroinflammation as well as methods and means useful for said active or passive immunization. | 07-22-2010 |
Pedro M. Alzari, Paris FR
Patent application number | Description | Published |
---|---|---|
20100055109 | POST-TRANSLATIONALLY MODIFIED NEUROTROPHINS - The present invention describes that neurotrophins undergo post-translational modifications, and that these post-translational modifications mediate the pro-apoptotic and/or pro-neurite activity of neurotrophins. These post-translational modifications notably include nitration and the formation of conformationally-different dimers, as well as of abnormal oligomers, such as tetramers and octamers. The invention further relates to compounds that compete with such modified neurotrophins, as well as to compounds that binds to said modified neurotrophins. The invention thus provides useful agents for the treatment of the conditions or diseases involving a chronic pain and/or neuron loss. | 03-04-2010 |
20140178384 | POST-TRANSLATIONALLY MODIFIED NEUROTROPHINS - The present invention describes that neurotrophins undergo post-translational modifications, and that these post-translational modifications mediate the pro-apoptotic and/or pro-neurite activity of neurotrophins. These post-translational modifications notably include nitration and the formation of conformationally-different dimers, as well as of abnormal oligomers, such as tetramers and octamers. The invention further relates to compounds that compete with such modified neurotrophins, as well as to compounds that binds to said modified neurotrophins. The invention thus provides useful agents for the treatment of the conditions or diseases involving chronic pain and/or neuron loss. | 06-26-2014 |